| Previous Close | 2.7 |
| Open | 2.84 |
| Day High | 3.05 |
| Day Low | 2.83 |
| 52-Week High | 7.73 |
| 52-Week Low | 2.56 |
| Volume | 5.66M |
| Average Volume | 3.85M |
| Market Cap | 258.59M |
| PE | -3.18 |
| EPS | -0.92 |
| Moving Average 50 Days | 2.95 |
| Moving Average 200 Days | 3.89 |
| Change | 0.23 |
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
GlobeNewswire Inc.
Feb 26, 2026 12:30 PM GMT
GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 202
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
GlobeNewswire Inc.
Jan 29, 2026 10:54 PM GMT
GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its previously announced register
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
GlobeNewswire Inc.
Jan 28, 2026 2:25 AM GMT
GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has entered into a securities purc